Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR88 | Q9GZN0 | 6/20 | 0.45 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.40 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.40 |
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | F7 | P08709 | 3/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16297751 | 1.00 | GPR88 (0.45) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL16297776 | 0.92 | ATM (0.43) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL8242542 | 0.92 | ATM (0.43) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL8239737 | 0.91 | ANPEP (0.43) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL16297806 | 0.91 | ANPEP (0.43) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL16297768 | 0.88 | GPR88 (0.46) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL8246550 | 0.88 | GPR88 (0.46) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL8245719 | 0.88 | MMP2 (0.47) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL8184380 | 0.87 | GPR88 (0.45) | GPR88ANPEPRNPEPDNPEPGPR139 | |
| SCHEMBL8239631 | 0.87 | GPR88 (0.45) | GPR88ANPEPRNPEPDNPEPGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385870-B1 | PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORP (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2006130686-A2 | HCV PROTEASE INHIBITORS IN COMBINATION WITH FOOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130687-A2 | LIVER/PLASMA CONCENTRATION RATIO FOR DOSING HEPATITIS C VIRUS PROTEASE INHIBITOR | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130553-A2 | HCV PROTEASE INHIBITORS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130552-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130607-A2 | CONTROLLED-RELEASE FORMULATION USEFUL FOR TREATING DISORDERS ASSOCIATED WITH HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130628-A2 | COMBINATION OF HCV PROTEASE INHIBITORS WITH A SURFACTANT | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130688-A2 | COMPOUNDS FOR INHIBITING CATHEPSIN ACTIVITY | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130626-A2 | METHOD FOR MODULATING ACTIVITY OF HCV PROTEASE THROUGH USE OF A NOVEL HCV PROTEASE INHIBITOR TO REDUCE DURATION OF TREATMENT PERIOD | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006130554-A2 | METHODS OF TREATING HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2003062265-A2 | NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS | SCHERING CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |